Augmedix vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco medical documentation company combining AI transcription with remote human scribes to produce EHR notes from physician-patient encounters in real time via smartphone or Glass.
About
Augmedix is a San Francisco-based medical documentation company that combines AI transcription technology with remote human scribes to document physician-patient encounters in real time, producing complete EHR notes that physicians review and sign. Physicians wear Google Glass or use a smartphone to stream audio and video of patient encounters to Augmedix's platform, where remote scribes observe and document the visit, supported by AI tools that transcribe speech and suggest note structures. This hybrid AI-plus-human model enables documentation quality and customization that pure AI solutions struggle to achieve for complex clinical encounters, while still dramatically reducing the time physicians spend on documentation. Augmedix serves large health systems and multispecialty groups, with customer deployments across hundreds of physicians. The company went public via merger with LifeSci Acquisition in 2020 and was subsequently acquired by Nuvation Bio. Augmedix competes with Nuance DAX, Suki, and traditional medical transcription services in the clinical documentation market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.